Quartet raises $17M series A

Analgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated.

Quartet is developing inhibitors of GTP cyclohydrolase 1 (GCH1) or sepiapterin reductase (SPR), which modulate tetrahydrobiopterin ( THB; BH4) synthesis, for chronic neuropathic pain indications. Quartet expects to have a lead candidate in preclinical development next year. ...